Episode Details

Summit Therapeutics Inc. (SMMT) Q2 2026 — Summit Therapeutics (SMMT) reported Q2 2026 after the close on July 23, 2026. GAAP net loss was $215.7M, or $(0.28)/share (last year's $(0.76) was inflated by a huge one-time stock-comp charge); the cleaner adjusted loss was $(0.19), a slight miss vs the ~$(0.17) estimate. Adjusted R&D jumped to $133.6M (+68% YoY) as the Phase III program scales; adjusted G&A was $18.2M. The company closed the quarter with $690.7M in cash and investments (up from $598.7M at Q1), after raising $230.8M via its ATM in Q2 plus $68.4M after quarter-end — but flagged going concern (resources insufficient for the next 12 months) and set up a new $380M ATM facility with JPMorgan. Six-month operating cash burn was $263.4M. The science broke Summit's way: the pivotal HARMONi trial's updated overall-survival analysis showed a hazard ratio of 0.76 in the full ITT population AND in both Western and Asian subgroups (Western median follow-up 23.2mo), answering the key geographic-translatability doubt; and Akeso's HARMONi-6 became the first Phase III to beat an approved PD-1 inhibitor head-to-head on OS (HR 0.66, p=0.0017) in 1L squamous NSCLC. Lead asset ivonescimab (PD-1/VEGF bispecific; Summit holds ex-China rights, Akeso licensor) has an FDA PDUFA date of November 14, 2026 in EGFR-mutated NSCLC post-TKI; HARMONi-3 (1L NSCLC) enrollment is complete with the squamous PFS readout due 2H 2026. The stock fell ~9% to ~$13.66 (near a 52-week low; 52-wk range $12.55–$30.98) on the going-concern/dilution overhang, a market cap ~$10.6B. Because SMMT is pre-revenue in its territories, we value it on a risk-adjusted sum-of-parts / reverse-DCF: net cash + probability-weighted rNPV of the ivonescimab programs lands a base fair value near $16 (~15–20% above the price), below the Street's ~$26 average target and $15–$38 range. Our call: HOLD, 3/5 — genuinely de-risking data and a hard November catalyst, but a single-asset, cash-burning, dilutive binary. Not financial advice. Summit Therapeutics is one of the most polarizing stories in biotech: a clinical-stage oncology company with no approved product and no revenue in the West, burning ~$140M a quarter, that the market still values near $10 billion. Why? Its lead drug, ivonescimab — a next-generation PD-1/VEGF bispecific antibody licensed from China's Akeso — may be best-in-class in lung cancer. In Q2 2026 the science broke Summit's way: the pivotal HARMONi trial showed an identical overall-survival benefit (hazard ratio 0.76) in Western and Asian patients as the data matured, and the HARMONi-6 study became the first Phase III ever to beat an approved PD-1 inhibitor head-to-head on survival (HR 0.66). An FDA decision is due November 14, 2026, and the big front-line HARMONi-3 readout is coming in the second half of the year. Yet the stock fell ~9% to ~$13.66 on the print — because the same report carried a going-concern warning and a new $380M stock-sale facility, meaning ongoing dilution. We value this pre-revenue, single-asset story on a risk-adjusted sum-of-parts and reverse-DCF: net cash plus the probability-weighted value of the pipeline lands our fair value near $16, only modestly above the price and below the Street's ~$26 average. Our call: HOLD, 3/5 — own it small for the optionality and the November catalyst, but respect that it's a binary that can halve on a bad print. Not financial advice. THE CALL: HOLD (3/5, DE-RISKING SCIENCE AND A HARD NOVEMBER CATALYST — BUT A SINGLE-ASSET, CASH-BURNING, DILUTIVE BINARY) — base-case value ~$16 vs ~$13.66 today. KEY METRICS: - GAAP net loss $215.7M, or $(0.28)/share (prior-year $(0.76) was inflated by one-time stock comp) - Adjusted (non-GAAP) net loss $147.0M, or $(0.19)/share — slight miss vs ~$(0.17) est - Adjusted R&D $133.6M (+68% YoY, GAAP $157.7M); adjusted G&A $18.2M (GAAP $62.8M) - Cash & investments $690.7M at quarter-end (up from $598.7M at Q1 2026); equity $630.0M - Raised $230.8M via ATM in Q2 + $68.4M post-quarter; 6